Navigation Links
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
Date:4/17/2013

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi , M.D., Ph.D. as its Senior Vice President and Chief Medical Officer.

Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry.  He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012.

"We welcome Paolo to Vanda and look forward to his leadership in strengthening our clinical organization," said Mihael H. Polymeropoulos , M.D., President and Chief Executive Officer of Vanda.

Dr. Baroldi previously served as the Senior Vice President and Chief Medical Officer of Vanda from July 2006 through January 2009.  He has served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis AG.

Dr. Baroldi holds M.D. and Ph.D. degrees from the University of Milan, Italy and is a member of the board of directors of Galileo Research. 

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Company Contact

Jim Kelly
Senior Vice President  & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... in product development and promotion has led to ... This mistrust, fueled by concerns about the insidious ... fed by reports of spectacular fines to the ... of industry suppression of negative clinical trial results, ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ... patient safety, clinical outcomes, and medication adherence. , ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ... Brown, SPIE Senior Director for Global Business Development. ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... Plague.” In this time period, doctors did not know ... at times, to the death of vulnerable patients. In ... don’t know that they may be unwittingly transmitting herpes ... study showed that severe fatigue contributed to latent herpes ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... (OTC Bulletin Board: MNCN), an innovative, global wellness solutions company, ... the OTC Bulletin Board under the symbol "MNCN." The Company,s ... , "The move to the OTC Bulletin Board will ... investors and help improve our trading liquidity," said Patrick Sheridan, ...
... DOR BioPharma, Inc. (OTC Bulletin Board: DORB) ... announced today that it has received a European ... technology for the improved oral delivery of drugs. ... Reverse Micelle Compositions and Uses Thereof" covers lipid ...
... July 8 iZumi Bio, Inc. and Pierian, Inc. ... company, iPierian, Inc. Building on the iZumi infrastructure and ... cellular reprogramming to change the paradigm of drug discovery. ... development of new therapeutics using induced pluripotent stem (iPS) ...
Cached Biology Technology:DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 2iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 3iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 4iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 5iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming 6
(Date:4/15/2014)... The global experts who study the deadliest infectious ... Thomas G. Ksiazek, professors at the University of Texas ... 6th annual International Symposium on Filoviruses. The filoviruses include ... to 90 percent of people infected. The current outbreak ... more than 100 deaths so far. , "This ...
(Date:4/15/2014)... 2014) The American Association of Anatomists (AAA) is ... awards will be presented during the Closing Awards Ceremony ... Tuesday, April 29th at 7:30 p.m. during AAA,s 2014 ... The 2014 award winners are: , Henry ... the Icahn School of Medicine at Mount Sinai, Past-President ...
(Date:4/15/2014)... deforestation could cause temperatures in the Congo Basin ... intensify warming caused by greenhouse gases by half, ... University of Leuven, Belgium. , Explosive population growth ... of tropical rainforests in Central Africa. A team ... how these practices will affect longer-term temperatures in ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3American Association of Anatomists 2014 award winners 2Study: Deforestation could intensify climate change in Congo Basin by half 2
... in German . , Innovations relating to mobility, ... KIT at the 2011 Hannover Messe from April 4 ... present a hybrid Porsche racing car, developments in battery research, ... a European energy supply system, and the Energy Solution Center ...
... the key to creating cyborg interfaces? Circuitry that links human ... as a robotic limb or artificial eye might one day ... Writing in the International Journal of Medical Engineering and ... can be made using human blood. Memristors were a theoretical ...
... that allow facilities to buy and sell emission allowances ... in the U.S. two decades ago. But critics worry ... low-income and minority communities. A new study ... of Public and Environmental Affairs, finds the problem hasn,t ...
Cached Biology News:KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5Blood simple circuitry for cyborgs 2Study: Emissions trading doesn't cause pollution 'hot spots' 2Study: Emissions trading doesn't cause pollution 'hot spots' 3
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Human PLUNC MAb (Clone 252512)...
... GRASP1 ( Abpromise for all ... Synthetic peptide corresponding to amino ... region of rat GRASP1, conjugated to ... Entrez GeneID: 56850 ...
Biology Products: